Company Cash Funds: Foghorn (FHTX)

Foghorn Therapeutics (FHTX) is innovating chromatin management via the Gene Traffic Control system for gene reprogramming. The cash balance history demonstrates liquidity dynamics, where 0.16 shapes the current metric. High risks are driven by the early stages of oncology drug development. Market capitalization relies on partnerships with pharma behemoths to create new tumor therapy methods.
Comprehensive metric breakdowns and analytics for Foghorn Therapeutics (FHTX)

This indicator aggregates all liquid funds in accounts, determining the issuer's ability to finance operating activities without incurring debt capital. The metric's value reacts immediately to quarterly reports and investment rounds. By analyzing cash asset dynamics, an investor assesses the company's margin of safety. For Foghorn Therapeutics (FHTX), this is critical, as cash volumes determine the pace of developing costly molecules until the moment of their commercialization.